In HFrEF, adding empagliflozin to medical therapy reduced a composite outcome, regardless of CKD status.
Where this comes from
- Record sourced from PubMed, PMID 34058113.
- Also identified by DOI 10.7326/ACPJ202106150-068.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Zannad F, Ferreira JP, Pocock SJ, et al. <b>Cardiac and kidney benefits of empagliflozin in heart failure across the spectrum of kidney function: insights from EMPEROR-Reduced.</b> Circulation. 2021;143:310-21. 33095032.
Medical subject headings
- Heart Failure
- Renal Insufficiency, Chronic